UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 158

Sortiert nach

Accurate and economical detection of ALK positive lung adenocarcinoma with semiquantitative immunohistochemical screening

PloS one, 2014-03, Vol.9 (3), p.e92828-e92828

2014

Volltextzugriff (PDF)

Blood tumor mutation burden can predict the clinical response to immune checkpoint inhibitors in advanced non-small cell lung cancer patients

Cancer Immunology, Immunotherapy, 2021-12, Vol.70 (12), p.3513-3524

2021

Volltextzugriff (PDF)

Driver Genes Associated With the Incidence of Venous Thromboembolism in Patients With Non-Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis

Frontiers in oncology, 2021-04, Vol.11, p.680191-680191

2021

Volltextzugriff (PDF)

Priming with LSD1 inhibitors promotes the persistence and antitumor effect of adoptively transferred T cells

Nature communications, 2024-05, Vol.15 (1), p.4327-4327, Article 4327

2024

Volltextzugriff (PDF)

CXCR6-positive circulating mucosal-associated invariant T cells can identify patients with non-small cell lung cancer responding to anti-PD-1 immunotherapy

Journal of experimental & clinical cancer research, 2024-05, Vol.43 (1), p.134-134, Article 134

2024

Volltextzugriff (PDF)

CD161 + CD127 + CD8 + T cell subsets can predict the efficacy of anti-PD-1 immunotherapy in non-small cell lung cancer with diabetes mellitus

Oncoimmunology, 2024-12, Vol.13 (1), p.2371575

2024

Volltextzugriff (PDF)

Advances in Diagnosis and Treatment of HER2-positive Non-small Cell Lung Cancer

Zhongguo fei ai za zhi, 2023-04, Vol.26 (4), p.291-302

2023

Volltextzugriff (PDF)

Clinical Characteristics, Co-Mutations, and Treatment Outcomes in Advanced Non-Small-Cell Lung Cancer Patients With the BRAF-V600E Mutation

Frontiers in oncology, 2022-06, Vol.12, p.911303-911303

2022

Volltextzugriff (PDF)

Crizotinib in patients with anaplastic lymphoma kinase-positive advanced non-small cell lung cancer versus chemotherapy as a first-line treatment

BMC cancer, 2018-01, Vol.18 (1), p.10-10, Article 10

2018

Volltextzugriff (PDF)

Mefatinib as first-line treatment of patients with advanced EGFR-mutant non-small-cell lung cancer: a phase Ib/II efficacy and biomarker study

Signal transduction and targeted therapy, 2021-11, Vol.6 (1), p.374-9, Article 374

2021

Volltextzugriff (PDF)

A Prediction Model for ROS1-Rearranged Lung Adenocarcinomas based on Histologic Features

PloS one, 2016-09, Vol.11 (9), p.e0161861-e0161861

2016

Volltextzugriff (PDF)

Stability Analysis of Low-Carbon Technology Innovation Cooperation under a Reward and Punishment Mechanism

Systems (Basel), 2022-08, Vol.10 (4), p.118

2022

Volltextzugriff (PDF)

Phase I study of icotinib hydrochloride (BPI-2009H), an oral EGFR tyrosine kinase inhibitor, in patients with advanced NSCLC and other solid tumors

Lung cancer (Amsterdam, Netherlands), 2011-08, Vol.73 (2), p.195-202

2011

Volltextzugriff (PDF)

CD57-positive CD8 + T cells define the response to anti-programmed cell death protein-1 immunotherapy in patients with advanced non-small cell lung cancer

NPJ precision oncology, 2024-01, Vol.8 (1), p.25-25, Article 25

2024

Volltextzugriff (PDF)

Effects of icotinib, a novel epidermal growth factor receptor tyrosine kinase inhibitor, in EGFR-mutated non-small cell lung cancer

Oncology reports, 2012-06, Vol.27 (6), p.2066-2072

2012

Volltextzugriff (PDF)

A high-throughput screen of pharmacologically active compounds for inhibitors of UHRF1 reveals epigenetic activity of anthracycline derivative chemotherapeutic drugs

Oncotarget, 2019-04, Vol.10 (32), p.3040-3050

2019

Volltextzugriff (PDF)

Overview of Multiplex Immunohistochemistry and Immunofluorescence Techniques  in the Lung Cancer Immunotherapy

Zhongguo fei ai za zhi, 2021-01, Vol.24 (1), p.36-42

2021

Volltextzugriff (PDF)

Progress on the Study of PD-L1 Detection Methods in Non-small Cell Lung Cancer

Zhongguo Fei Ai Za Zhi, 2019, Vol.22 (1), p.40-44

2019

Volltextzugriff (PDF)

A pooled analysis of clinical outcome in driver-gene negative non-small cell lung cancer patients with MET overexpression treated with gumarontinib

Therapeutic advances in medical oncology, 2024-01, Vol.16, p.17588359241264730

2024

Volltextzugriff (PDF)

Josephin domain containing 2 (JOSD2) promotes lung cancer by inhibiting LKB1 (Liver kinase B1) activity

Signal transduction and targeted therapy, 2024-01, Vol.9 (1), p.11-11, Article 11

2024

Volltextzugriff (PDF)

Updated overall survival and circulating tumor DNA analysis of ensartinib for crizotinib‐refractory ALK‐positive NSCLC from a phase II study

Cancer communications (London, England), 2024-04, Vol.44 (4), p.455-468

2024

Volltextzugriff (PDF)

Prognostic Analysis of EGFR-TKIs Combined with Gamma Knife in EGFR-mutant Lung Adenocarcinoma with Brain Metastasis

Zhongguo fei ai za zhi, 2019-05, Vol.22 (5), p.312-318

2019

Volltextzugriff (PDF)

Immunomodulatory effects of CDK4/6 inhibitors

Biochimica et biophysica acta. Reviews on cancer, 2023-07, Vol.1878 (4), p.188912-188912, Article 188912

2023

Volltextzugriff (PDF)

Efficacy and safety of pembrolizumab plus chemotherapy and sequential surgical resection in initial unresectable stage IIIB NSCLC

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.e20595-e20595

2023

Volltextzugriff (PDF)

Evaluating the Effect of Chinese Environmental Regulation on Corporate Sustainability Performance: The Mediating Role of Green Technology Innovation

International journal of environmental research and public health, 2022-06, Vol.19 (11), p.6882

2022

Volltextzugriff (PDF)

1 – 25 von 158

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(124)
Mit Volltextzugriff
(151)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(110)
Life Sciences & Biomedicine
(63)
Humans
(39)
Oncology
(37)
Physical Sciences
(35)
Technology
(35)
Lung Cancer
(28)
Female
(22)
Lung Neoplasms - Genetics
(18)
Chemistry
(17)
Male
(16)
Mutation
(16)
Materials Science
(15)
Non-Small Cell Lung Cancer
(15)
Materials Science, Multidisciplinary
(14)
Adult
(12)
Lung Neoplasms - Drug Therapy
(12)
Proteins
(12)
Tumors
(12)
Cancer Therapies
(11)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

Menü

Weitere Dienste

Einstellungen

Accurate and economical detection of ALK positive lung adenocarcinoma with semiquantitative immunohistochemical screening

Blood tumor mutation burden can predict the clinical response to immune checkpoint inhibitors in advanced non-small cell lung cancer patients

Driver Genes Associated With the Incidence of Venous Thromboembolism in Patients With Non-Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis

Priming with LSD1 inhibitors promotes the persistence and antitumor effect of adoptively transferred T cells

CXCR6-positive circulating mucosal-associated invariant T cells can identify patients with non-small cell lung cancer responding to anti-PD-1 immunotherapy

CD161 + CD127 + CD8 + T cell subsets can predict the efficacy of anti-PD-1 immunotherapy in non-small cell lung cancer with diabetes mellitus

Advances in Diagnosis and Treatment of HER2-positive Non-small Cell Lung Cancer

Clinical Characteristics, Co-Mutations, and Treatment Outcomes in Advanced Non-Small-Cell Lung Cancer Patients With the BRAF-V600E Mutation

Crizotinib in patients with anaplastic lymphoma kinase-positive advanced non-small cell lung cancer versus chemotherapy as a first-line treatment

Mefatinib as first-line treatment of patients with advanced EGFR-mutant non-small-cell lung cancer: a phase Ib/II efficacy and biomarker study

A Prediction Model for ROS1-Rearranged Lung Adenocarcinomas based on Histologic Features

Stability Analysis of Low-Carbon Technology Innovation Cooperation under a Reward and Punishment Mechanism

Phase I study of icotinib hydrochloride (BPI-2009H), an oral EGFR tyrosine kinase inhibitor, in patients with advanced NSCLC and other solid tumors

CD57-positive CD8 + T cells define the response to anti-programmed cell death protein-1 immunotherapy in patients with advanced non-small cell lung cancer

Effects of icotinib, a novel epidermal growth factor receptor tyrosine kinase inhibitor, in EGFR-mutated non-small cell lung cancer

A high-throughput screen of pharmacologically active compounds for inhibitors of UHRF1 reveals epigenetic activity of anthracycline derivative chemotherapeutic drugs

Overview of Multiplex Immunohistochemistry and Immunofluorescence Techniques  in the Lung Cancer Immunotherapy

Progress on the Study of PD-L1 Detection Methods in Non-small Cell Lung Cancer

A pooled analysis of clinical outcome in driver-gene negative non-small cell lung cancer patients with MET overexpression treated with gumarontinib

Josephin domain containing 2 (JOSD2) promotes lung cancer by inhibiting LKB1 (Liver kinase B1) activity

Updated overall survival and circulating tumor DNA analysis of ensartinib for crizotinib‐refractory ALK‐positive NSCLC from a phase II study

Prognostic Analysis of EGFR-TKIs Combined with Gamma Knife in EGFR-mutant Lung Adenocarcinoma with Brain Metastasis

Immunomodulatory effects of CDK4/6 inhibitors

Efficacy and safety of pembrolizumab plus chemotherapy and sequential surgical resection in initial unresectable stage IIIB NSCLC

Evaluating the Effect of Chinese Environmental Regulation on Corporate Sustainability Performance: The Mediating Role of Green Technology Innovation

Suchergebnisse filtern